William Blair Expands Biopharmaceuticals Coverage in Equity Research and Institutional Sales and Trading

Wednesday, August 2, 2017

William Blair, a global investment banking and asset management firm, is pleased to announce that it is expanding its coverage of the biopharmaceuticals industry across the firm’s equity research and institutional sales and trading teams.

“As the pace of innovation in life sciences accelerates and researchers are on the brink of breakthroughs in numerous disease areas, biotechnology and biopharmaceutical companies will play an increasingly important role in helping healthcare systems around the world control costs and deliver improved patient outcomes,” said John Moore, William Blair’s head of institutional equities, sales, trading, and research. “We are committed to providing our clients best-in-class service and insights into this vital sector.”

As part of the expansion of its biopharma franchise, William Blair has announced a series of new roles and promotions:

Equity Research:

  • Andy Hsieh, Matt Phipps, and Raju Prasad will be promoted to senior research analysts in William Blair’s equity research team, bringing the number of senior analysts covering biopharma to six.
  • Amanda Murphy will expand her existing biopharma and diagnostic services equity research coverage to include companies focused on gene sequencing and gene editing technologies.
  • Tim Lugo and Katherine Xu will become co-group heads of William Blair’s biopharma equity research team.

Institutional Sales and Trading:

  • John Mullaly has been promoted to global healthcare coverage specialist; his responsibilities will include a focus on the firm’s biopharma specialist institutional investor base and healthcare-focused institutional portfolio managers.

William Blair also recently announced that it has reorganized its healthcare equity research coverage into two groups focusing on the biopharma and healthcare technology sectors, reflecting the growth and increased specialization of these verticals. Over the past several years, interest in biopharma by institutional investors has surged, creating greater need for in-depth research coverage of the space and sales professionals focused on working with funds and portfolio managers who specialize in the industry.

“We believe that the recent promotions and additional resources we have dedicated to biopharma will enable us to significantly expand our biotech research coverage list and provide our clients even deeper levels of service and access to novel investment ideas,” said John O’Toole, William Blair’s director of equity research.

About William Blair
William Blair is a global investment banking and asset management firm. We are committed to building enduring relationships with our clients and providing expertise and solutions to meet their evolving needs. An independent and employee-owned firm, William Blair is based in Chicago, with offices in 10 cities worldwide. For more information, please visit williamblair.com.

News Alerts

Stay connected to your favorite publications and news features.

Subscribe Now